Cholesterol Ester Transfer Proteins
"Cholesterol Ester Transfer Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins that bind to and transfer CHOLESTEROL ESTERS between LIPOPROTEINS such as LOW-DENSITY LIPOPROTEINS and HIGH-DENSITY LIPOPROTEINS.
| Descriptor ID |
D053480
|
| MeSH Number(s) |
D09.400.430.750 D12.776.124.197 D12.776.157.165 D12.776.395.199
|
| Concept/Terms |
Cholesterol Ester Transfer Proteins- Cholesterol Ester Transfer Proteins
- Cholesteryl Ester Exchange Protein
- Cholesteryl Ester Transfer Protein
- Cholesterol Ester Transport Protein, CETP
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol Ester Transfer Proteins".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol Ester Transfer Proteins".
This graph shows the total number of publications written about "Cholesterol Ester Transfer Proteins" by people in this website by year, and whether "Cholesterol Ester Transfer Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 2 | 0 | 2 |
| 2009 | 1 | 3 | 4 |
| 2010 | 2 | 0 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 5 | 1 | 6 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholesterol Ester Transfer Proteins" by people in Profiles.
-
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025 05 17; 405(10491):1757-1768.
-
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trials. Pharmacol Res Perspect. 2024 Dec; 12(6):e70010.
-
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity. Curr Opin Lipidol. 2024 Dec 01; 35(6):303-309.
-
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis. Alzheimers Res Ther. 2024 Oct 16; 16(1):228.
-
CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysis. Front Endocrinol (Lausanne). 2024; 15:1359780.
-
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib. J Clin Pharmacol. 2024 Sep; 64(9):1150-1164.
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
-
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep. 2024 02; 26(2):35-44.
-
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition. Eur Heart J Cardiovasc Pharmacother. 2023 02 02; 9(2):148-155.
-
The relationship between high density lipoprotein cholesterol and sepsis: A clinical and genetic approach. Clin Transl Sci. 2023 03; 16(3):489-501.